Isis Pharmaceuticals (NASDAQ: [[ticker:ISIS]]), the Carlsbad, CA-based company that uses antisense technology to make targeted drugs, will receive a $35 million upfront cash payment from GlaxoSmithKline as part of a new collaboration announced today. The deal covers research into rare disorders and infectious diseases, in up to as many as six programs. Isis is eligible to receive milestone payments worth as much as $1.5 billion combined if all six programs are successful, plus double-digit royalties on sales if any of them become marketed products.
Author: Luke Timmerman
Luke is an award-winning journalist specializing in life sciences. He has served as national biotechnology editor for Xconomy and national biotechnology reporter for Bloomberg News. Luke got started covering life sciences at The Seattle Times, where he was the lead reporter on an investigation of doctors who leaked confidential information about clinical trials to investors. The story won the Scripps Howard National Journalism Award and several other national prizes. Luke holds a bachelor’s degree in journalism from the University of Wisconsin-Madison, and during the 2005-2006 academic year, he was a Knight Science Journalism Fellow at MIT.
View all posts by Luke Timmerman
